FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Subscribe To Our Newsletter & Stay Updated
